Repeat mediastinoscopy after neo-adjuvant chemotherapy in stage III (N-2) non-small cell lung cancer (NSCLC)?

被引：0
|
作者：
Maesen, B
Snijder, R
Elbers, J
delaRiviere, AB
Schramel, F
机构：
[1] ST ANTONIUS HOSP,DEPT PULMONOL,NIEUWEGEIN,NETHERLANDS
[2] ST ANTONIUS HOSP,DEPT PATHOL,NIEUWEGEIN,NETHERLANDS
[3] ST ANTONIUS HOSP,DEPT THORAC SURG,NIEUWEGEIN,NETHERLANDS
来源：
EUROPEAN JOURNAL OF CANCER | 1997年 / 33卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：1052 / 1052
页数：1
相关论文
共 50 条
  • [21] Prognostic Roles of Neoadjuvant and Adjuvant Chemotherapy for Treating Patients with Operable Stage III-N2 Non-Small Cell Lung Cancer (NSCLC)
    Yong, L.
    Kuo, S.
    Yang, P.
    Huang, P.
    Lin, M.
    Chen, K.
    Lee, J.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S708 - S708
  • [22] Phase II trial of gemcitabine-carboplatin-paclitaxel (GCP) as neo-adjuvant chemotherapy for operable non-small cell lung cancer (NSCLC)
    Abratt, R
    Lee, J
    Han, J
    Tsai, C
    Boyer, M
    Mok, T
    Kim, S
    Lee, J
    Brnabic, A
    Lehnert, M
    LUNG CANCER, 2005, 49 : S92 - S92
  • [23] Phase II trial of gemcitabine-carboplatin-paclitaxel (GCP) as neo-adjuvant chemotherapy for operable non-small cell lung cancer (NSCLC).
    Abratt, RP
    Lee, JS
    Han, JY
    Tsai, CM
    Boyer, M
    Mok, T
    Kim, SW
    Lee, JS
    Brnabic, AJM
    Lehnert, M
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 685S - 685S
  • [24] Phase II trial of neo-adjuvant gemeltabine-carboplatin-paclitaxel (GCP) chemotherapy for operable non-small cell lung cancer (NSCLC)
    Abratt, R. P.
    Lee, J. S.
    Han, J. Y.
    Tsai, C. M.
    Boyer, M.
    Mok, T.
    Kim, S. W.
    Lee, J. S.
    Brnabic, A. J. M.
    Lehnert, M.
    EJC SUPPLEMENTS, 2005, 3 (02): : 339 - 339
  • [25] Predictive And Prognostic Role Of Metabolic Response In Patients With Non-Small Cell Lung Carcinoma (NSCLC) Treated With Neo-adjuvant Chemotherapy
    Castello, A.
    Toschi, L.
    Rossi, S.
    Finocchiaro, G.
    Grizzi, F.
    Qehajaj, D.
    Lopci, E.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2018, 45 : S171 - S172
  • [26] Docetaxel as neo-adjuvant therapy for radically treatable stage III non-small cell lung cancer: early results of an international phase III study
    Mattson, K
    Abratt, R
    Ten, GV
    Krofta, K
    Tonelli, D
    Avril, I
    LUNG CANCER, 2001, 34 : S21 - S23
  • [27] RADIOTHERAPY FOR STAGE III NON-SMALL CELL LUNG CANCER (NSCLC)
    De Ruysscher, D.
    LUNG CANCER, 2009, 64 : S21 - S21
  • [28] Adjuvant chemotherapy and radiotherapy in the treatment of non-small cell lung cancer (NSCLC)
    Zaric, Bojan
    Stojsic, Vladimir
    Tepavac, Aleksandar
    Sarcev, Tatjana
    Zarogoulidis, Paul
    Darwiche, Kaid
    Tsakiridis, Kosmas
    Karapantzos, Ilias
    Kesisis, Georgios
    Kougioumtzi, Ioanna
    Katsikogiannis, Nikolaos
    Machairiotis, Nikolaos
    Stylianaki, Aikaterini
    Foroulis, Christophoros N.
    Zarogoulidis, Konstantinos
    Perin, Branislav
    JOURNAL OF THORACIC DISEASE, 2013, 5 : S371 - S377
  • [29] Adjuvant chemotherapy for early stage non-small cell lung cancer
    Patel, Manali L.
    Wakelee, Heather A.
    FRONTIERS IN ONCOLOGY, 2011, 1
  • [30] SAKK 16/14: Anti-PD-L1 antibody durvalumab in addition to neo-adjuvant chemotherapy in patients with stage IIIA(N2) non-small cell lung cancer (NSCLC)
    Rothschild, S. I.
    Zippelius, A.
    Eboulet, E. I.
    Savic, S.
    Betticher, D.
    Bettini, A.
    Fruh, M.
    Jorger, M.
    Britschgi, C.
    Peters, S.
    Mark, M.
    Ochsenbein, A. F.
    Janthur, W. -D.
    Waibel, C.
    Mach, N.
    Gonzalez, M.
    Frosch, P.
    Goddar, G.
    Rusterholz, C.
    Pless, M.
    SWISS MEDICAL WEEKLY, 2020, : 3S - 3S
12345